144 related articles for article (PubMed ID: 28710329)
1. Open-label trial of ranolazine for the treatment of myotonia congenita.
Arnold WD; Kline D; Sanderson A; Hawash AA; Bartlett A; Novak KR; Rich MM; Kissel JT
Neurology; 2017 Aug; 89(7):710-713. PubMed ID: 28710329
[TBL] [Abstract][Full Text] [Related]
2. Open-label trial of ranolazine for the treatment of paramyotonia congenita.
Lorusso S; Kline D; Bartlett A; Freimer M; Agriesti J; Hawash AA; Rich MM; Kissel JT; David Arnold W
Muscle Nerve; 2019 Feb; 59(2):240-243. PubMed ID: 30390395
[TBL] [Abstract][Full Text] [Related]
3. Sodium channel slow inactivation as a therapeutic target for myotonia congenita.
Novak KR; Norman J; Mitchell JR; Pinter MJ; Rich MM
Ann Neurol; 2015 Feb; 77(2):320-32. PubMed ID: 25515836
[TBL] [Abstract][Full Text] [Related]
4. The mechanism underlying transient weakness in myotonia congenita.
Myers JH; Denman K; DuPont C; Hawash AA; Novak KR; Koesters A; Grabner M; Dayal A; Voss AA; Rich MM
Elife; 2021 Apr; 10():. PubMed ID: 33904400
[TBL] [Abstract][Full Text] [Related]
5. The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study.
Andersen G; Hedermann G; Witting N; Duno M; Andersen H; Vissing J
Brain; 2017 Sep; 140(9):2295-2305. PubMed ID: 29050397
[TBL] [Abstract][Full Text] [Related]
6. Aerobic training in myotonia congenita: Effect on myotonia and fitness.
Andersen G; Løkken N; Vissing J
Muscle Nerve; 2017 Oct; 56(4):696-699. PubMed ID: 28039888
[TBL] [Abstract][Full Text] [Related]
7. Contractile properties of the abductor digiti minimi muscle in paramyotonia congenita.
Burke D; Skuse NF; Lethlean AK
J Neurol Neurosurg Psychiatry; 1974 Aug; 37(8):894-9. PubMed ID: 4423558
[TBL] [Abstract][Full Text] [Related]
8. Quantification of mobility impairment and self-assessment of stiffness in patients with myotonia congenita by the physiotherapist.
Hammarén E; Kjellby-Wendt G; Lindberg C
Neuromuscul Disord; 2005 Oct; 15(9-10):610-7. PubMed ID: 16084086
[TBL] [Abstract][Full Text] [Related]
9. Ranolazine reduces angina frequency and severity and improves quality of life: Observational study in patients with chronic angina under ranolazine treatment in Greece (OSCAR-GR).
Alexopoulos D; Kochiadakis G; Afthonidis D; Barbetseas J; Kelembekoglou P; Limberi S; Spanos A; Triantafyllidis G
Int J Cardiol; 2016 Feb; 205():111-116. PubMed ID: 26730841
[TBL] [Abstract][Full Text] [Related]
10. Diffusely increased insertional activity: "EMG disease" or asymptomatic myotonia congenita? A report of 2 cases.
Mitchell CW; Bertorini TE
Arch Phys Med Rehabil; 2007 Sep; 88(9):1212-3. PubMed ID: 17826470
[TBL] [Abstract][Full Text] [Related]
11. Myotonia congenita--a cause of muscle weakness and stiffness.
Chrestian N; Puymirat J; Bouchard JP; Dupré N
Nat Clin Pract Neurol; 2006 Jul; 2(7):393-9; quiz following 399. PubMed ID: 16932590
[TBL] [Abstract][Full Text] [Related]
12. A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images.
Venkataraman R; Belardinelli L; Blackburn B; Heo J; Iskandrian AE
JACC Cardiovasc Imaging; 2009 Nov; 2(11):1301-9. PubMed ID: 19909934
[TBL] [Abstract][Full Text] [Related]
13. Transient muscular weakness in severe recessive myotonia congenita. Improvement of isometric muscle force by drugs relieving myotomic stiffness.
Ricker K; Haass A; Hertel G; Mertens HG
J Neurol; 1978 Aug; 218(4):253-62. PubMed ID: 81274
[TBL] [Abstract][Full Text] [Related]
14. Effect of mexiletine on transitory depression of compound motor action potential in recessive myotonia congenita.
Lo Monaco M; D'Amico A; Luigetti M; Desaphy JF; Modoni A
Clin Neurophysiol; 2015 Feb; 126(2):399-403. PubMed ID: 25065301
[TBL] [Abstract][Full Text] [Related]
15. Impact of ranolazine on coronary microvascular dysfunction (MICRO) study.
Ahmed B; Mondragon J; Sheldon M; Clegg S
Cardiovasc Revasc Med; 2017 Sep; 18(6):431-435. PubMed ID: 28576663
[TBL] [Abstract][Full Text] [Related]
16. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
Chaitman BR; Pepine CJ; Parker JO; Skopal J; Chumakova G; Kuch J; Wang W; Skettino SL; Wolff AA;
JAMA; 2004 Jan; 291(3):309-16. PubMed ID: 14734593
[TBL] [Abstract][Full Text] [Related]
17. Clinical study of paramyotonia congenita with and without myotonia in a warm environment.
Haass A; Ricker K; Rüdel R; Lehmann-Horn F; Böhlen R; Dengler R; Mertens HG
Muscle Nerve; 1981; 4(5):388-95. PubMed ID: 6793868
[TBL] [Abstract][Full Text] [Related]
18. Neuromuscular excitability changes produced by sustained voluntary contraction and response to mexiletine in myotonia congenita.
Ginanneschi F; Mignarri A; Lucchiari S; Ulzi G; Comi GP; Rossi A; Dotti MT
Neurophysiol Clin; 2017 Jun; 47(3):247-252. PubMed ID: 28153715
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of mexiletine in non-dystrophic myotonias: A randomised, double-blind, placebo-controlled, cross-over study.
Vicart S; Franques J; Bouhour F; Magot A; Péréon Y; Sacconi S; Nadaj-Pakleza A; Behin A; Zahr N; Hézode M; Fournier E; Payan C; Lacomblez L; Fontaine B
Neuromuscul Disord; 2021 Nov; 31(11):1124-1135. PubMed ID: 34702654
[TBL] [Abstract][Full Text] [Related]
20. Novel CLCN1 mutation in carbamazepine-responsive myotonia congenita.
Lyons MJ; Duron R; Molinero I; Sangiuolo F; Holden KR
Pediatr Neurol; 2010 May; 42(5):365-8. PubMed ID: 20399394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
